Today

Agents

Chat

Arena

Discover

More

App

Arrowhead Pharmaceuticals Q3 EPS USD -1.36 - ARWR News | Rallies

Arrowhead Pharmaceuticals Q3 EPS USD -1.36

ARWR•2026-08-04

Q3 results

Aug. 4 (Reuters) - Arrowhead Pharmaceuticals Q3 operating expenses were USD 245.346 million.

Q3 revenue was USD 75.253 million versus the IBES estimate of USD 54.3 million
Q3 operating income was USD -170.093 million

Related News

Latham Q2 2026 net income falls 20.19% to $12.75 million; net sales rise 14.39% to $197.47 million

SWIM•2026-08-04

Paramount Skydance reports mixed second quarter as Warner deal faces March trial

PSKY•2026-08-04

Alaska Air swings to GAAP pretax loss of $214 million in Q2 FY26; revenue rises 10% to $4.07 billion

ALK•2026-08-04

Viasat Q1 FY27 adjusted EBITDA falls 7% to $381 million; revenue dips 1% to $1.16 billion

VSAT•2026-08-04

Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26

CSTL•2026-08-04